Sangamo Image
Sangamo Therapeutics (SGMO) suffered through a second year of price declines prompted by ineffective clinical responses to their lead clinical gene editing or GE therapies. The company responded by placing all three GE clinical programs on hold as they work to increase dosing safely to levels needed for efficacy. This dropped by my estimated valuation mix for GE from about 34% to just 2% (Table 1).
Author graphic
Despite this setback, the overall valuation increased substantially led by the success of SB 525, a gene therapy or GT for hemophilia A